secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2026-08-06T20:10:29+00:00
Accession:  0001725160-26-000061
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis Q2 2026 cash $174.6M; DENALI Part 2 topline readout expected 1H 2027
-----------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $174.6M as of June 30, 2026, providing runway into late 2027.
- R&D expenses $35.2M (up $7.6M YoY) driven by $7.0M milestone payment for ASPENOVA Phase 3 start and increased clinical costs.
- Total operating expenses $44.4M for Q2 2026 vs $36.1M in Q2 2025.
- FDA Type D meeting: no objection to azenosertib 400mg QD 5:2 dose for Cyclin E1-positive PROC; accelerated approval strategy intact.
- DENALI Part 2 enrollment complete in Parts 2a/2b; Part 2c enrolling; integrated topline readout expected 1H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000061/0001725160-26-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000061/zntl-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001725160-26-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer